Implementation and Uptake of Raltegravir Granules in Newborns Diagnosed With HIV Through Birth Testing in Maternity Settings in Zimbabwe During the COVID-19 Pandemic.
Lise Denoeud-NdamCarl SteckerPrecious AndifasiAngela MushaviTalent MaphosaMongiwa ZondoMildrate MuranduGladys GombakombaLeila KatirayiMore MungatiRebecca BaileyRachel WeberEmilia RivadeneiraSusan HrapcakPublished in: The Pediatric infectious disease journal (2023)
Zimbabwe introduced raltegravir (RAL) granules at 14 facilities providing point-of-care HIV birth testing, aiming to initiate all newborns with HIV on a RAL-based regimen. From June 2020 to July 2021, we tested 3172 of the 6989 (45%) newborns exposed to HIV; we diagnosed 59(2%) with HIV infection, of whom 27 (46%) initiated RAL. The SARS-CoV-2 coronavirus disease pandemic exacerbated supply chain and trained provider shortages, contributing to low birth testing, RAL uptake and 6-month viral load testing.
Keyphrases
- antiretroviral therapy
- hiv testing
- hiv positive
- hiv infected
- gestational age
- hiv infected patients
- sars cov
- coronavirus disease
- men who have sex with men
- human immunodeficiency virus
- hiv aids
- hepatitis c virus
- pregnant women
- cord blood
- preterm birth
- south africa
- low birth weight
- respiratory syndrome coronavirus
- healthcare
- body composition
- pregnancy outcomes
- preterm infants